Cargando…

Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19

COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammator...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Samuel K., McSweeney, Morgan D., Pickles, Raymond J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836766/
https://www.ncbi.nlm.nih.gov/pubmed/33276017
http://dx.doi.org/10.1016/j.jconrel.2020.11.057

Ejemplares similares